Skip to main content

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In What does "Remember Me" do?

Don't Know Your Password?
Help

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In

Don't Know Your Password?

Zacks

more

Evofem Biosciences (EVFM)

(Delayed Data from OTC)

$0.01 USD

0.00 (-5.37%)

Updated May 31, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.08%
2	Buy	17.91%
3	Hold	9.44%
4	Sell	5.10%
5	Strong Sell	2.55%
S&P	500	11.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Evofem Biosciences, Inc. [EVFM]

Reports for Purchase

Showing records 41 - 60 ( 118 total )

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 41

01/31/2020

Industry Report

Pages: 3

Yas'' Weekly Recap of Our Key Notes and 12 Doc Calls Upcoming in 1H20

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 42

01/29/2020

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 43

01/28/2020

Pages: 11

Appetite for Amphora Is High Based on Our Proprietary Survey (n

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 44

01/24/2020

Industry Report

Pages: 2

Healthcare - Yas'' Weekly Recap of Our Key Notes and 9 Doc Calls Upcoming in 1Q20

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 45

01/10/2020

Industry Report

Pages: 11

Healthcare Join Our 1Q20 Doc Call Series

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 46

12/27/2019

Industry Report

Pages: 3

Yas'' Weekly Recap of Our Key Notes

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 47

12/27/2019

Industry Report

Pages: 6

Part 2: "Must-See" Companies at JPM (Mkt. Cap. $100M-$499M) With 1Q20 Catalysts

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 48

12/20/2019

Industry Report

Pages: 3

Healthcare - Yas'' Weekly Recap of Our Key Notes

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 49

12/19/2019

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 50

12/19/2019

Pages: 5

Healthcare-Expert Call Recap for 2019 in Women''s Health

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 51

12/18/2019

Pages: 4

Amphora Is Getting Closer - Closer to the Finish Line

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 52

12/18/2019

Pages: 4

Amphora Resubmission Accepted for Review; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 53

12/11/2019

Pages: 5

AMPREVENCE Delivers; Reiterate Buy; Raising Target to $11

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 54

12/02/2019

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 55

12/02/2019

Pages: 4

Amphora Runs Circles Around Other Contraceptives with New AMPREVENCE data

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 56

11/29/2019

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 57

11/27/2019

Pages: 4

Let the Countdown to Potential Launch Begin

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 58

11/27/2019

Pages: 5

Amphora Resubmitted; Launch Next Year; 3Q19 Financials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 59

11/08/2019

Pages: 2

Healthcare - Earnings Recap: Halftime Show of Our Most In-Depth, Differentiated Earnings Yet

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Evofem Biosciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 60

11/07/2019

Pages: 12

3Q19 - Amphora Plays Its Cards Right; Affirm Buy

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party